Issue: Vol. 43

Towards better biocatalysts: advances in high throughput screening and data-driven design of immobilized enzymes

Enzyme immobilization is a critical technology to enhance the stability and reusability of biocatalysts for industrial applications. However, traditional immobilization development is still tied to trial-and-error approaches, which are time-consuming and often lead to a suboptimal preparation. In this article, we aim to discuss the latest developments in the integration of high throughput experimentation, bioinformatics and data driven tools for the design and development of novel immobilized enzymes.

Read More »

Asymmetric hydrogenation of olefins with transition metal-based catalysts: practical insights from screening to production of APIs

Selective hydrogenation plays a critical role in modern synthetic chemistry, particularly in the pharmaceutical industry, where the production of chiral molecules with high enantiomeric purity is essential for the efficacy and safety of active pharmaceutical ingredients (APIs). By enabling the selective introduction of stereogenic centers, metal catalyzed hydrogenation processes are often the key to achieving the desired pharmacological properties. This article reviews both the historical evolution and modern strategies for developing enantioselective hydrogenation processes, focusing on a real case study where process optimization has been extensively studied to meet industrial requirements.

Read More »

Biocatalysis in the pharmaceutical industry: beyond sustainability, towards efficiency

The application of biocatalysis into chemical processes is a fast-growing area driven by its potential benefits towards manufacturing sustainability.
The recent applications are unlocking the design of enzymatic machineries capable of executing unimaginable reactivities with great precision and satisfactory yields in “greener” condition. However, to adequately scale-up the designed biocatalytic route to the industrial level, several other features must be guaranteed, such as enzyme production and overall cost effectiveness. These concepts will be described through two case studies that occurred in our laboratories.

Read More »

One catalyst to rule them all: a journey from bulk to atom-level control

In this overview, the principles underlying the evolution of catalysis over time through the transition from homogeneous to heterogeneous catalysis and the more recent single-atom catalysis, and its strong impact on both academia and industry will be explored and discussed. This article discusses the crucial role of catalysis in both academic research and industrial applications, with advances often motivated by the need for more sustainable, selective, and efficient chemical transformations. Several examples of the application of catalysis techniques and their development are reported, offering insights into needs and prospects in different fields. Here, homogeneous catalysis, the development of nanoreactors and supramolecular systems, and single-atom catalysis are explored, presenting a concise overview of these milestones and discussing how frontier research is shaping the future of catalysis.

Read More »

Catalysis as a Key Technology for the Development and Implementation of Cost-Competitive and Sustainable Production of Active Pharmaceutical Ingredients (APIs)

Catalysis plays a central role in the synthesis of active pharmaceutical ingredients (APIs), offering enhanced efficiency, selectivity, and sustainability in modern pharmaceutical manufacturing. The demand for greener and more cost-effective synthesis routes has positioned catalytic methods—particularly asymmetric, enzymatic, and transition-metal catalysis—at the forefront of pharmaceutical innovation. This article explores the various types of catalysis used in API production, discusses process design considerations, and highlights future perspectives for catalysis in the pharmaceutical sector.

Read More »

Distress to Recovery: Solutions for EU Chemical SMEs Overcoming Energy Costs, Inflation and Debt in Challenging Times

European fine & specialty chemical manufacturers are struggling with input cost increases, supply-chain disruptions and decreased access to traditional debt-financing. These factors have pushed many Small-Medium sized Enterprises (SMEs) – defined as firms from 5-50MM€ in sales – into financial distress. This article explains how partnering with an M&A Advisor can help distressed businesses identify inorganic methods of stabilizing a firm’s financial position, including Distressed & Special Operations Funds (DSOP), Distressed Debt Funds (DDF) and others.

Read More »

Concentration and complexity: how formulation is the lynchpin for biologic development

The development of biologics, like monoclonal antibodies (mAbs), Antibody-drug conjugates (ADCs) and bispecific antibodies, has provided treatment for diseases once deemed untreatable, such as advanced cancers and autoimmune disorders. As powerful as these biologics are, their development still come with substantial technical challenges.
Behind every biologic drug is a formulation that ensures the molecule’s stability, safety and efficacy. This unassuming yet critical component must handle the inherent complexity of biologics and their sensitivity to environmental factors like pH and temperature, while maintaining efficacy and manufacturability at scale. Increasingly, formulation efforts also address a key patient-centric need: transitioning therapies from intravenous (IV) to subcutaneous (SC) formats. High-concentration formulations are central to SC delivery, but they introduce new technical hurdles that demand a great deal of expertise.

Read More »

Login